In the relentless quest for groundbreaking cancer therapies, innovative drug trials are reshaping treatment landscapes and redefining patient hope. Arcus Biosciences Inc. (NYSE:RCUS) on Monday announced new monotherapy data for casdatifan in late-line metastatic clear cell renal cell carcinoma (ccRCC).ARC-20 is a Phase 1/1b dose-escalation and expansion study with four monotherapy cohorts (n=121): 50mg twice daily (BID), 50mg once daily (QD), 100mg QD (tablet), and 150mg QD.New Casdatifan DataIn the 100mg t ...

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for immunology and inflammation (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [2] - The company aims to create best-in-class therapies by targeting established mechanisms of action and utilizing advanced antibody engineering to enhance properties such as half-life [2] - APG777 is the most advanced program, targeting AD, which is identified as the largest and least penetrated market within I&I [2] Pipeline and Strategy - Apogee has four validated targets in its portfolio and is pursuing both monotherapies and combinations of its novel antibodies to achieve best-in-class profiles [2] - The company believes its broad pipeline and expertise can provide significant value and benefits to patients who are underserved by current standard care [2] Upcoming Events - Management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025, at 11:30 a.m. E.T., with a live and archived webcast available on the company's website [1]